Warning BioSpecifics Technologies Corp. (NASDAQ:BSTC) optimists! Thomas Wegman just Sold 10,849 shares.

Share with your friends










Submit

Warning BioSpecifics Technologies Corp optimists! Thomas Wegman just Sold 10849 shares-Transactions

Thomas Wegman Insider Sell Transaction

Seeing the trade Thomas Wegman made he is in in the stock market eye today. The President & CEO of BioSpecifics Technologies Corp. (NASDAQ:BSTC) and an insider, unloaded 10,849 shares worth $543,342 U.S Dollars. The average price was $50.1 per share. It seems he is very active lately as in the last month, he silently unloaded additional 27,151 shares of the company, worth $1,423,704 USD. The chance that this transaction remains hidden is little as a result of the enormous amount of cash involved. Now, Thomas Wegman owns 136,822 shares which are equivalent to roughly 10%+ of the Company’s total market capitalization.

Biospecifics Technologies Corp Stock Rating, Sentiment and Fundamentals

Mr. Thomas Wegman might have executed this transaction because he’s very negative and trusts there’s a cloudy future for Biospecifics Technologies Corp and its stock price.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:SELL
Hedge Funds Sentiment:BUY
Stock Fundamentals
Earnings + FCF Trend:SELL
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:DOWN
MT Trend:NEUTRAL
LT Trend:UP
OctaFinance Rating*:SELL

* Read How Our Stock Ratings System Works

Within the last 75 days, the share price of Biospecifics Technologies Corp has declined by exactly 14.44 % and is in a strong and steady downtrend. We rate Biospecifics Technologies Corp’s stock as sell not just because of the insider sell by Thomas but also in accordance with OctaFinance’s proprietary equities time momentum system as presented on the chart below.

Price Chart of Biospecifics Technologies Corp NASDAQ:BSTC Stock

Warning BioSpecifics Technologies Corp optimists! Thomas Wegman just Sold 10849 shares-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

As Paul Tudor Jones, one of the market legends, stated, that the highest returns are made through a combination of technical and fundamental analysis.”

Hedge Funds Ownership

Data gathered from SEC filings, show that 81 hedge funds own Biospecifics Technologies Corp. The tracked institutional and hedge funds have historically had a high interest in the company’s stock, and that was also the case in the last quarter. The institutional ownership was 42.62 % of the stock’s outstanding shares. They increased by 299,648 the total shares they hold. As of that quarter these stock owners owned 2.95 million shares. A total of 11 funds opened new positions in Biospecifics Technologies Corp and 36 increased their holdings. There were 5 funds that closed their positions and 24 that reduced them.

HEDGE-FUNDS-LIST-DATABASE-FREE

Apis Capital Advisors Llc is the most bullish institutional investor on Biospecifics Technologies Corp, with ownership of 75,964 shares as of Q2 2015 for 4.40% of the fund’s portfolio. Jw Asset Management Llc is another bullish institutional investor owning 61,557 shares of the company or 0.97% of their stocks portfolio. The stock is also 0.85% of the fund’s AUM. The California-based fund Magee Thomson Investment Partners Llc have less than 0.01% of their stock portfolio invested in the company’s market cap for 152 shares. Moreover, William Leland Edwards’s Palo Alto Investors Llc revealed it had acquired a stake worth 0.12% of the fund’s stock portfolio in the company. Rk Capital Management Llc was also a notable believer in the firm, owning 117,206 shares. Biospecifics Technologies Corp is 1.09% of the fund’s stock portfolio.

BioSpecifics Technologies Corp NASDAQ:BSTC Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that the Company may pursue, including human and canine lipoma. The Company generates revenue primarily from Auxilium pursuant to the Second Amended and Restated Development and License Agreement with Auxilium (Auxilium Agreement). Under the Auxilium Agreement, the Company receives license, sublicense income, royalties, milestones and mark-up on cost of goods sold payments related to the sale and approval of XIAFLEX.

Company Website: BioSpecifics Technologies Corp

Biospecifics Technologies Corp was founded in Delaware on 1990-11-01. At the moment its market capitalization is: $320.58 million and it has 6.41 million outstanding shares. The firm has 5 employees. Today it has 50.76% shareholders and the institutional ownership is 50.76%. The stock closed at $49.490002 yesterday and it had average 2 days volume of 20893 shares. It is up from the 30 days average shares volume of 17735. Biospecifics Technologies Corp has a 52w low of $35.50 and a 52 weeks high of $71.49. The stock price is above the 200 days Simple moving average.

* All shares sold at $50. The reporting person undertakes to provide – upon request by the staff of the Securities and Exchange Commission – the issuer – or a security holder of the issuer – full information regarding the number of shares sold at each separate price.

* The selling price of $50.0892 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $50.00 to $50.15. The reporting person undertakes to provide – upon request by the staff of the Securities and Exchange Commission – the issuer – or a security holder of the issuer – full information regarding the number of shares sold at each separate price

BioSpecifics Technologies Corp - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.